Copyright Reports & Markets. All rights reserved.

Global Angina Pectoris Treatment Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Angina Pectoris Treatment Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Angina Pectoris Treatment Market Size Growth Rate by Product
      • 1.4.2 Antiplatelet agents
      • 1.4.3 Beta-adrenergic blocking agents
      • 1.4.4 Calcium channel blockers
      • 1.4.5 Short & Long – acting Nitroglycerines
      • 1.4.6 Angiotensin-converting enzyme (ACE) inhibitors
      • 1.4.7 Anti-ischemic agents
    • 1.5 Market by End User
      • 1.5.1 Global Angina Pectoris Treatment Market Size Growth Rate by End User
      • 1.5.2 Hospitals
      • 1.5.3 Clinic
      • 1.5.4 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Angina Pectoris Treatment Market Size
      • 2.1.1 Global Angina Pectoris Treatment Revenue 2014-2025
      • 2.1.2 Global Angina Pectoris Treatment Sales 2014-2025
    • 2.2 Angina Pectoris Treatment Growth Rate by Regions
      • 2.2.1 Global Angina Pectoris Treatment Sales by Regions
      • 2.2.2 Global Angina Pectoris Treatment Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Angina Pectoris Treatment Sales by Manufacturers
      • 3.1.1 Angina Pectoris Treatment Sales by Manufacturers
      • 3.1.2 Angina Pectoris Treatment Sales Market Share by Manufacturers
      • 3.1.3 Global Angina Pectoris Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2 Angina Pectoris Treatment Revenue by Manufacturers
      • 3.2.1 Angina Pectoris Treatment Revenue by Manufacturers (2014-2019)
      • 3.2.2 Angina Pectoris Treatment Revenue Share by Manufacturers (2014-2019)
    • 3.3 Angina Pectoris Treatment Price by Manufacturers
    • 3.4 Angina Pectoris Treatment Manufacturing Base Distribution, Product Types
      • 3.4.1 Angina Pectoris Treatment Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Angina Pectoris Treatment Product Type
      • 3.4.3 Date of International Manufacturers Enter into Angina Pectoris Treatment Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Angina Pectoris Treatment Sales by Product
    • 4.2 Global Angina Pectoris Treatment Revenue by Product
    • 4.3 Angina Pectoris Treatment Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Angina Pectoris Treatment Breakdown Data by End User

    6 North America

    • 6.1 North America Angina Pectoris Treatment by Countries
      • 6.1.1 North America Angina Pectoris Treatment Sales by Countries
      • 6.1.2 North America Angina Pectoris Treatment Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Angina Pectoris Treatment by Product
    • 6.3 North America Angina Pectoris Treatment by End User

    7 Europe

    • 7.1 Europe Angina Pectoris Treatment by Countries
      • 7.1.1 Europe Angina Pectoris Treatment Sales by Countries
      • 7.1.2 Europe Angina Pectoris Treatment Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Angina Pectoris Treatment by Product
    • 7.3 Europe Angina Pectoris Treatment by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Angina Pectoris Treatment by Countries
      • 8.1.1 Asia Pacific Angina Pectoris Treatment Sales by Countries
      • 8.1.2 Asia Pacific Angina Pectoris Treatment Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Angina Pectoris Treatment by Product
    • 8.3 Asia Pacific Angina Pectoris Treatment by End User

    9 Central & South America

    • 9.1 Central & South America Angina Pectoris Treatment by Countries
      • 9.1.1 Central & South America Angina Pectoris Treatment Sales by Countries
      • 9.1.2 Central & South America Angina Pectoris Treatment Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Angina Pectoris Treatment by Product
    • 9.3 Central & South America Angina Pectoris Treatment by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Angina Pectoris Treatment by Countries
      • 10.1.1 Middle East and Africa Angina Pectoris Treatment Sales by Countries
      • 10.1.2 Middle East and Africa Angina Pectoris Treatment Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Angina Pectoris Treatment by Product
    • 10.3 Middle East and Africa Angina Pectoris Treatment by End User

    11 Company Profiles

    • 11.1 Abbott Laboratories Inc.
      • 11.1.1 Abbott Laboratories Inc. Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Abbott Laboratories Inc. Angina Pectoris Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Abbott Laboratories Inc. Angina Pectoris Treatment Products Offered
      • 11.1.5 Abbott Laboratories Inc. Recent Development
    • 11.2 Astra Zeneca plc
      • 11.2.1 Astra Zeneca plc Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Astra Zeneca plc Angina Pectoris Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Astra Zeneca plc Angina Pectoris Treatment Products Offered
      • 11.2.5 Astra Zeneca plc Recent Development
    • 11.3 Bayer AG
      • 11.3.1 Bayer AG Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Bayer AG Angina Pectoris Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Bayer AG Angina Pectoris Treatment Products Offered
      • 11.3.5 Bayer AG Recent Development
    • 11.4 Bristol-Myers Squibb Company
      • 11.4.1 Bristol-Myers Squibb Company Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Bristol-Myers Squibb Company Angina Pectoris Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Bristol-Myers Squibb Company Angina Pectoris Treatment Products Offered
      • 11.4.5 Bristol-Myers Squibb Company Recent Development
    • 11.5 F. Hoffmann-La Roche Ltd
      • 11.5.1 F. Hoffmann-La Roche Ltd Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 F. Hoffmann-La Roche Ltd Angina Pectoris Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 F. Hoffmann-La Roche Ltd Angina Pectoris Treatment Products Offered
      • 11.5.5 F. Hoffmann-La Roche Ltd Recent Development
    • 11.6 Forest Laboratories Inc
      • 11.6.1 Forest Laboratories Inc Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Forest Laboratories Inc Angina Pectoris Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Forest Laboratories Inc Angina Pectoris Treatment Products Offered
      • 11.6.5 Forest Laboratories Inc Recent Development
    • 11.7 Gilead Sciences, Inc
      • 11.7.1 Gilead Sciences, Inc Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Gilead Sciences, Inc Angina Pectoris Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Gilead Sciences, Inc Angina Pectoris Treatment Products Offered
      • 11.7.5 Gilead Sciences, Inc Recent Development
    • 11.8 GlaxoSmithKline plc
      • 11.8.1 GlaxoSmithKline plc Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 GlaxoSmithKline plc Angina Pectoris Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 GlaxoSmithKline plc Angina Pectoris Treatment Products Offered
      • 11.8.5 GlaxoSmithKline plc Recent Development
    • 11.9 Novartis AG
      • 11.9.1 Novartis AG Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Novartis AG Angina Pectoris Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Novartis AG Angina Pectoris Treatment Products Offered
      • 11.9.5 Novartis AG Recent Development
    • 11.10 Pfizer Inc.
      • 11.10.1 Pfizer Inc. Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Pfizer Inc. Angina Pectoris Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Pfizer Inc. Angina Pectoris Treatment Products Offered
      • 11.10.5 Pfizer Inc. Recent Development
    • 11.11 Sanofi SA

    12 Future Forecast

    • 12.1 Angina Pectoris Treatment Market Forecast by Regions
      • 12.1.1 Global Angina Pectoris Treatment Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Angina Pectoris Treatment Revenue Forecast by Regions 2019-2025
    • 12.2 Angina Pectoris Treatment Market Forecast by Product
      • 12.2.1 Global Angina Pectoris Treatment Sales Forecast by Product 2019-2025
      • 12.2.2 Global Angina Pectoris Treatment Revenue Forecast by Product 2019-2025
    • 12.3 Angina Pectoris Treatment Market Forecast by End User
    • 12.4 North America Angina Pectoris Treatment Forecast
    • 12.5 Europe Angina Pectoris Treatment Forecast
    • 12.6 Asia Pacific Angina Pectoris Treatment Forecast
    • 12.7 Central & South America Angina Pectoris Treatment Forecast
    • 12.8 Middle East and Africa Angina Pectoris Treatment Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Angina Pectoris Treatment Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Angina Pectoris Treatment market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Angina Pectoris Treatment market based on company, product type, end user and key regions.

      This report studies the global market size of Angina Pectoris Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Angina Pectoris Treatment in these regions.
      This research report categorizes the global Angina Pectoris Treatment market by top players/brands, region, type and end user. This report also studies the global Angina Pectoris Treatment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Abbott Laboratories Inc.
      Astra Zeneca plc
      Bayer AG
      Bristol-Myers Squibb Company
      F. Hoffmann-La Roche Ltd
      Forest Laboratories Inc
      Gilead Sciences, Inc
      GlaxoSmithKline plc
      Novartis AG
      Pfizer Inc.
      Sanofi SA

      Market size by Product
      Antiplatelet agents
      Beta-adrenergic blocking agents
      Calcium channel blockers
      Short & Long – acting Nitroglycerines
      Angiotensin-converting enzyme (ACE) inhibitors
      Anti-ischemic agents
      Market size by End User
      Hospitals
      Clinic
      Other

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Angina Pectoris Treatment market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Angina Pectoris Treatment market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Angina Pectoris Treatment companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Angina Pectoris Treatment submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Angina Pectoris Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Angina Pectoris Treatment market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now